Evaluative Epidemiology Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto nazionale dei Tumori, Milan, Italy; Digestive Cancer Registry of Burgundy, Dijon University Hospital, Dijon, France; INSERM CTM UMR 1231 EPICAD, University of Burgundy, Dijon, France.
Editorial Board, Epidemiologia e Prevenzione, Milan, Italy.
Eur J Cancer. 2024 Sep;208:114187. doi: 10.1016/j.ejca.2024.114187. Epub 2024 Jul 9.
To estimate net survival and cancer cure fraction (CF), i.e. the proportion of patients no longer at risk of dying from cancer progression/relapse, a clear distinction needs to be made between mortality from cancer and from other causes. Conventionally, CF is estimated assuming no excess mortality compared to the general population.
A new modelling approach, that corrects for patients' extra risk of dying (RR) from causes other than the diagnosed cancer, was considered to estimate both indicators. We analysed EUROCARE-6 data on head and neck (H&N), colorectal, and breast cancer patients aged 40-79, diagnosed from 1998 to 2002 and followed-up to 31/12/2014, provided by 65 European cancer registries.
Young male H&N cancer patients have 4 times the risk of dying from other causes than their peers, this risk decreases with age to 1.6. Similar results were observed for female. We observed an absolute increase in CF of 30 % using the new model instead of the conventional one. For colorectal cancer, CF with the new model increased by a maximum of 3 % for older patients and the RR ranged from 1 to 1.2 for both sexes. CF of female breast cancer ranged from 73 % to 79 % using the new cure model, with RR between 1.2 and 1.4.
Not considering a RR> 1 leads to underestimate the proportion of patients not bound to die of their diagnosed cancer. Estimates of cancer mortality risk have an important impact on patients' quality of life.
为了估计净生存和癌症治愈分数(CF),即不再有死于癌症进展/复发风险的患者比例,需要明确区分癌症死亡和其他原因死亡。传统上,假设 CF 与普通人群相比没有超额死亡率。
为了估计这两个指标,我们考虑了一种新的建模方法,该方法纠正了患者因除诊断癌症以外的原因而额外死亡的风险(RR)。我们分析了来自 65 个欧洲癌症登记处的 1998 年至 2002 年诊断、随访至 2014 年 12 月 31 日的 40-79 岁头颈部(H&N)、结直肠癌和乳腺癌患者的 EUROCARE-6 数据。
年轻男性 H&N 癌症患者死于其他原因的风险是同龄人的 4 倍,该风险随着年龄的增长而降低至 1.6。女性也观察到类似的结果。与传统模型相比,使用新模型可使 CF 绝对增加 30%。对于结直肠癌,使用新模型时,老年患者的 CF 最多增加 3%,RR 为 1 至 1.2。新治愈模型的女性乳腺癌 CF 范围为 73%至 79%,RR 在 1.2 至 1.4 之间。
不考虑 RR>1 会导致低估不会死于诊断癌症的患者比例。癌症死亡率的估计对患者的生活质量有重要影响。